23andMe’s new Type 2 Diabetes report* offers customers insight into their likelihood of developing one of the most prevalent, pernicious, and yet preventable health conditions in the United States.
To help you take the next step in your wellness journey, Lark and 23andMe have teamed up to offer customers the opportunity to integrate their genetic results into coaching programs to spur you toward your health goals this year.
This week 23andMe added a new Carrier Status report on familial Mediterranean fever, a genetic disorder that can include periodic fevers and inflammation in the abdomen, chest or joints.
The U.S. Food and Drug Administration (FDA) granted 23andMe authorization to offer reports to customers on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications.
Today, 23andMe received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk for its BRCA1/BRCA2 (Selected Variants) report.
ZDogg — aka Dr. Zubin Damania, a doctor and a hip-hop humorist of healthcare — was in the house at 23andMe last week, for a conversation with our CEO and co-founder Anne Wojcicki for his Facebook Live show, Incident Report.
A new survey found that most Americans are interested in using DNA testing to understand more about their health and ancestry, but the national survey also revealed a need for better education around the science of genetics.
Last week, 23andMe released two new genetic health risk reports for customers.
23andMe recently started offering customers new Genetic Health Risk reports that have received FDA authorization. Below we’ve highlighted some important features in these reports to help you get more out of them.
The U.S. Food and Drug Administration granted 23andMe authorization to offer 10 genetic health risk reports including late-onset Alzheimer’s disease, Parkinson’s disease, celiac disease and a condition associated with harmful blood clots.
